616888-34-7

Upstream product

• 192940-81-1 1-(t-butoxycarbonyl)-3-phenyl-3-(2-hydroxyethyl)pyrrolidine 
• 140-29-4 phenylacetonitrile 
• 92248-94-7 3-cyano-3-phenyl-glutaric acid dimethyl ester 
• 1014702-72-7 C₁₃H₁₅NO₃ 
• 52423-63-9 2-(3-phenyl-5-yl-pyrrolidin-3-yl)-ethanol 

Downstream Products

• 1014702-75-0 C₃₀H₄₁N₃O₂ 
• 1014702-73-8 C₃₀H₄₁N₅O₃ 
• 1014702-76-1 C₂₃H₃₅N₃O₂ 
• 1014703-42-4 C₂₈H₃₅N₇O 
• 1014702-77-2 C₃₂H₄₁N₅O₃ 
• 1014703-06-0 C₃₃H₄₃N₇O₃ 
• 1014701-42-8 5-(5-{2-[1-(3,3-difluoro-cyclobutanecarbonyl)-3-phenyl-pyrrolidin-3-yl]-ethyl}-hexahydro-pyrrolo[3,4-c]pyrrole-2-carbonyl)-4,6-dimethyl-pyridine-2-carbonitrile 
• 1014702-45-4 (5-{2-[1-(3,3-difluoro-cyclobutanecarbonyl)-3-phenyl-pyrrolidin-3-yl]-ethyl}-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-(3,5-dimethyl-1-pyrimidin-5-yl-1H-pyrazol-4-yl)-methanone 
• 1014702-79-4 C₃₅H₄₃F₃N₆O₃ 
• 1014701-47-3 {5-[2-(1-cyclopenanecarbonyl-3-phenyl-pyrrolidin-1-yl)-ethyl]-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl}-[3,5-dimethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazol-4-yl]-methanone 

Relevant academic research and scientific papers

Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles

Replacement of a secondary amide with an N-acyl or N-sulfonyl gem-disubstituted azacyle in a series of CCR5 antagonists led to the identification of compounds with excellent in vitro HIV antiviral activity and increased intrinsic membrane permeability.

OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo [3.3.0] octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula (I).